Details for New Drug Application (NDA): 209803
✉ Email this page to a colleague
The generic ingredient in STEGLATRO is ertugliflozin. One supplier is listed for this compound. Additional details are available on the ertugliflozin profile page.
Summary for 209803
| Tradename: | STEGLATRO |
| Applicant: | Msd Sub Merck |
| Ingredient: | ertugliflozin |
| Patents: | 1 |
Suppliers and Packaging for NDA: 209803
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| STEGLATRO | ertugliflozin | TABLET;ORAL | 209803 | NDA | Merck Sharp & Dohme LLC | 0006-5363 | 0006-5363-03 | 30 TABLET, FILM COATED in 1 BOTTLE (0006-5363-03) |
| STEGLATRO | ertugliflozin | TABLET;ORAL | 209803 | NDA | Merck Sharp & Dohme LLC | 0006-5363 | 0006-5363-06 | 90 TABLET, FILM COATED in 1 BOTTLE (0006-5363-06) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
| Approval Date: | Dec 19, 2017 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Jul 13, 2030 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES | ||||||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 15MG | ||||
| Approval Date: | Dec 19, 2017 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Jul 13, 2030 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES | ||||||||
Complete Access Available with Subscription
